Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Guardian Pharmacy Services to post earnings of $0.22 per share and revenue of $329.57 million for the quarter.
Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.01). The business had revenue of $329.31 million during the quarter, compared to analyst estimates of $321.21 million. On average, analysts expect Guardian Pharmacy Services to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Guardian Pharmacy Services Stock Performance
NYSE:GRDN traded up $0.24 during mid-day trading on Wednesday, hitting $21.00. 4,913 shares of the company traded hands, compared to its average volume of 156,902. The stock's fifty day moving average price is $20.65 and its 200-day moving average price is $21.47. Guardian Pharmacy Services has a one year low of $14.16 and a one year high of $26.91.
Analyst Ratings Changes
Several analysts have issued reports on the company. Raymond James Financial set a $28.00 price target on Guardian Pharmacy Services and gave the company an "outperform" rating in a report on Wednesday, May 14th. Wall Street Zen upgraded Guardian Pharmacy Services from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Truist Financial restated a "buy" rating and issued a $28.00 price objective (up from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th.
Check Out Our Latest Analysis on GRDN
Insiders Place Their Bets
In other news, Director John Ackerman sold 1,084,276 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $21,859,004.16. Following the transaction, the director directly owned 200,099 shares in the company, valued at $4,033,995.84. The trade was a 84.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Fred Burke sold 747,102 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $15,061,576.32. Following the completion of the sale, the insider owned 551,724 shares in the company, valued at $11,122,755.84. This represents a 57.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,344,912 shares of company stock valued at $228,713,426. Insiders own 63.71% of the company's stock.
Institutional Investors Weigh In On Guardian Pharmacy Services
An institutional investor recently bought a new position in Guardian Pharmacy Services stock. Dynamic Technology Lab Private Ltd bought a new position in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,975 shares of the company's stock, valued at approximately $233,000.
Guardian Pharmacy Services Company Profile
(
Get Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
Read More
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
